<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03741972</url>
  </required_header>
  <id_info>
    <org_study_id>ICO-2018-03-PA-Glucosur</org_study_id>
    <nct_id>NCT03741972</nct_id>
  </id_info>
  <brief_title>Metabolic and Hemodynamic Effects of the Inhibitors of Type 2 Sodium Glucose Co-transporters (ISGLT2) in Diabetic Patients With Heart Failure</brief_title>
  <acronym>GLUCOSUR-IC</acronym>
  <official_title>Metabolic and Hemodynamic Effects of the Inhibitors of Type 2 Sodium Glucose Co-transporters (ISGLT2) in Diabetic Patients With Heart Failure. GLUCOSUR-IC Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Germans Trias i Pujol Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Germans Trias i Pujol Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inhibitors of the type 2 sodium-glucose co-transporter (iSGLT2) may improve the metabolic and
      hemodynamic profile in patients with DM2 and heart failure.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 21, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in cardiac biomarkers</measure>
    <time_frame>12 months</time_frame>
    <description>Changes in cardiac biomarkers: NTproBNP, CA125 and ST2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life: EuroQol-5D questionnaire (EuroQol five dimension questionnaire)</measure>
    <time_frame>12 months</time_frame>
    <description>Changes in patient's quaility of life by 5Q questionnaire (EuroQol standardised, non-disease-specific instrument for health-related quality of life with 2 parts: first one score from 3-3-3-3 (worst) to 1-1-1-1 (best) and second one which a visual scale scores form 0 (worst)-100 (best). EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208. El EuroQol-5D: una alternativa sencilla para la medición de la calidad de vida relacionada con la salud en atención primaria. Aten Primaria 2001; 28:425-429.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of pulmonary congestion</measure>
    <time_frame>12 months</time_frame>
    <description>Changes in pulmonary congestion by pulmonary echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improve in the 6-minute walk</measure>
    <time_frame>12 months</time_frame>
    <description>Changes in functional capacity by the 6 minute-walk</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <description>Patients with diabetes and heart failure that are treated with iSGLT2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iSGTL2</intervention_name>
    <description>Treatment with empaglifozine 10 mg/day (may be also dapaglifozine 10mg/day depending on clinical trial results)</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients with type 2 diabetes and heart failure who attend a university
        hospital heart failure unit.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 Diabetes

          -  HbA1c&gt; 6.5%

          -  Estimated GF&gt; 45 ml / min

          -  BMI: ≥25 Kg / m2

          -  Stable pharmacological treatment of Heart Failure in the last 3 months

        Exclusion Criteria:

          -  Diabetes type 1 or type LADA (presence of antibodies against GAD and/or IA-2 positive)

          -  DM2 with C-peptide &lt;1 ng / mL

          -  GEF &lt;45 ml / min

          -  Recurrent urinary tract infections
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nuria Alonso Pedrol</last_name>
    <role>Principal Investigator</role>
    <affiliation>Germans Trias i Pujol Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mar Domingo</last_name>
    <phone>0034934978772</phone>
    <email>madote@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Germans Trias i Pujol University Hospital</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoni Bayés Genís</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 12, 2018</study_first_submitted>
  <study_first_submitted_qc>November 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2018</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Germans Trias i Pujol Hospital</investigator_affiliation>
    <investigator_full_name>Antoni Bayés Genís</investigator_full_name>
    <investigator_title>Chief of the Cardiology Unit</investigator_title>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>Diabetes</keyword>
  <keyword>iSGLT2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

